Full text is available at the source.
The management of hypothalamic obesity in craniopharyngioma
Managing weight gain caused by damage to the brain's appetite control after craniopharyngioma
AI simplified
Abstract
Hypothalamic obesity (HO) results from hypothalamic injury and is associated with impaired leptin-melanocortin signaling.
- HO is characterized by disrupted energy balance, leading to hyperphagia and reduced sympathetic tone.
- Conventional lifestyle modifications are largely ineffective for managing HO.
- Pharmacotherapeutic approaches targeting neuroendocrine and metabolic pathways may be necessary.
- Dextroamphetamine has shown effectiveness in some HO patients.
- Emerging therapies include melanocortin-4 receptor agonists and GLP-1 receptor agonists, which could enhance satiety and energy expenditure.
- Long-term efficacy and safety of these therapies require further validation.
AI simplified